A small, retrospective study at Johns Hopkins has found that, in patients with particular pancreatic duct lesions, the presence of an inherited mutation in a pancreatic cancer susceptibility gene may increase the patients’ risk of developing pancreatic cancer.
As the Galleri test is advancing toward becoming the first multi-cancer detection test to secure FDA approval, cancer care providers are coming up with strategies for using these tests responsibly.
